This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 384 studies, archived under the term: "Other"

Click here to filter this large number of results.

Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial

Importance: Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to assess potential disease-modifying agents in clinical trials. To our knowledge, this is the first report of a randomized trial to prospectively enrich a study population with prodromal AD (PDAD) defined by cerebrospinal fluid (CSF) biomarker criteria and mild […]

Treatment effects of therapeutic cholinesterase inhibitors on visuospatial processing in Alzheimer’s disease: A longitudinal functional MRI study

Background/Aims: Visuospatial impairments are known to occur in Alzheimer’s disease (AD). We hypothesised that functional magnetic resonance imaging (fMRI) response in task-related brain regions would be impaired in patients with AD during the task and that treatment with acetyl cholinesterase inhibitors would enhance activations in brain regions concerned with this visual perceptual processing. Method: Ten […]

Improving patient-centered care for people dementia in medical encounters: An educational intervention for old age psychiatrists

Background: Health care professionals are recommended to deliver patient-centered care in dementia; however, guidance and training on how to do this in practice is currently lacking. The aim of this study was to develop and evaluate pragmatically an educational intervention for old age psychiatrists to promote patient-centered care in their consultations with people with dementia […]

No effect of donepezil on striatal dopamine release in mild to moderate Alzheimer’s disease

Objective: Work in experimental animals suggests that an interaction with dopaminergic networks might explain some of the therapeutic effects of the cholinesterase inhibitor class of drugs. This study aimed to test whether acute (single 5 mg) or 4–8 weeks (5–10 mg) of treatment with oral donepezil would elicit measurable striatal dopamine (DA) release in patients […]

A prospective study on the use of rivastigmine transdermal patch in Alzheimer’s dementia in a routine clinical setting

There is not much published literature on the use of rivastigmine patch in a “routine” clinical setting. Objectives: In this naturalistic longitudinal observational study we sought to evaluate the safety, tolerability and efficacy of the rivastigmine patch in patients with early and late onset moderate Alzheimer’s disease in a routine clinical setting. Methods: Out of […]

Improving decision‐making for feeding options in advanced dementia: A randomized, controlled trial

Objectives: To test whether a decision aid improves quality of decision‐making about feeding options in advanced dementia. Design: Cluster randomized controlled trial. Setting: Twenty‐four nursing homes in North Carolina. Participants: Residents with advanced dementia and feeding problems and their surrogates. Intervention: Intervention surrogates received an audio or print decision aid on feeding options in advanced […]

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer disease: A post hoc analysis

Objective: To investigate the tolerability and efficacy of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease receiving concomitant memantine. Research design and methods: Post hoc analysis of a 25-week, randomized, prospective, open-label, parallel-group study. Patients receiving donepezil were switched to rivastigmine patches (4.6 mg/24 h) immediately or following a 7-day withdrawal for 4 […]

Efficacy and tolerability of Ginkgo biloba extract EGb 761® by type of dementia: Analyses of a randomised controlled trial

Secondary analyses of a randomised controlled trial were performed to find out whether treatment effects of Ginkgo biloba extract EGb 761® differed by type of dementia. Three hundred ninety-five patients aged 50 years or above, with dementia with neuropsychiatric features were treated with EGb 761® (240 mg/day) or placebo for 22 weeks. Patients scored between […]

Ginkgo biloba prevention trials: More than an ounce of prevention learned

Objective: To determine effectiveness of G biloba vs placebo in reducing the incidence of all-cause dementia and Alzheimer disease (AD) in elderly individuals with normal cognition and those with mild cognitive impairment (MCI). Design, Setting, and Participants: Randomized, double-blind, placebo-controlled clinical trial conducted in 5 academic medical centers in the United States between 2000 and […]

Long-term treatment of patients with Alzheimer’s disease in primary and secondary care: Results from an international survey

Objective: The International Outcomes Survey in Dementia (IOSID) was initiated to observe the effects of current standard of care for Alzheimer’s disease (AD) on patient outcomes and caregiver burden in a real-life setting. Research design and methods: This 2-year, international, prospective, longitudinal and observational cohort survey involved patients with mild-to-moderate AD (Mini-Mental State Examination [MMSE] […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below: